#South Korea #Seoul #Cancer Research #Lunit #ASCO 2026

Lunit Showcases AI-Driven Oncology Studies at ASCO 2026

Lunit, a prominent player in AI-enhanced cancer diagnostics, is set to make waves at the upcoming ASCO 2026 Annual Meeting, taking place from May 29 to June 2 in Chicago, IL. The company will present five innovative studies focused on precision oncology and biomarker-driven research, effectively widening the scope of traditional immune profiling.

This year's presentations highlight an evolution in Lunit's approach, moving towards integrated AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. These efforts aim to characterize various cancer parameters such as HER2 expression, immune phenotypes, and tumor-infiltrating lymphocytes, showcasing the transformative potential of AI in patient stratification across multiple cancer types.

Among the prominent studies, one led by experts from Yonsei University College of Medicine investigates a first-line quadruplet treatment regimen for HER2-positive advanced biliary tract cancer (BTC). Presented as a Rapid Oral Presentation at ASCO 2026, this trial evaluates the effectiveness of trastuzumab, nivolumab, gemcitabine, and cisplatin. Utilizing AI-powered whole-slide image analysis, the research team analyzed HER2 expression and various immune phenotypes across different tumor tissues. They reported that 40 enrolled patients achieved an objective response rate (ORR) of 55%, with a remarkable disease control rate (DCR) of 95%. Furthermore, those with HER2 IHC 3+ tumor cell populations exceeding 10% demonstrated significantly higher response rates, underscoring AI's role in identifying patients who may benefit from targeted therapies.

Additionally, an insightful study examined the tumor microenvironment of HER2-overexpressing non-small cell lung cancer (NSCLC). Leveraging AI for spatial analysis, researchers analyzed over 2,000 NSCLC whole-slide images and found that tumors with high HER2 expression exhibited reduced tumor-infiltrating lymphocyte density and a lower inflamed immune phenotype. This suggests that heightened HER2 levels may correlate with immune evasion in tumors—an important finding in understanding the biological implications of HER2 overexpression.

In a separate study conducted in partnership with Seoul National University Hospital, the researchers focused on the rare adenoid cystic carcinoma (ACC). They discovered that patients exhibiting high densities of endothelial cells and tumor-infiltrating lymphocytes experienced significantly longer progression-free survival (19.6 months vs. 11.1 months) with axitinib treatment. This research advocates for AI's application in identifying subgroups that traditional biomarkers may miss, shining a light on tailored treatment opportunities.

Another illuminating study from Asan Medical Center explored the tumor microenvironment in metastatic microsatellite-stable (MSS) colorectal cancer, a cohort known for its resistance to immune checkpoint inhibitors. The research identified that larger tertiary lymphoid structure regions, as recognized by AI, provided a positive correlation to improved outcomes following immunotherapy. Such insights position AI as an indispensable tool in assessing which MSS colorectal cancer patients may respond favorably to immunotherapeutic strategies.

As Lunit's CEO, Brandon Suh, commented, "We are witnessing a paradigm shift in biomarker analysis, where AI is the catalyst for innovations beyond conservative methodologies. Our integrated approach not only enhances precision in research but supports informed patient stratification and treatment response evaluations."

Lunit is demonstrating its AI biomarker platforms and collaborative research initiatives at ASCO 2026, underlining its commitment to evolving cancer care and enhancing patient outcomes globally. Lunit’s solutions have already made significant impacts through their FDA-cleared Lunit INSIGHT Breast Suite and its partnership with pharmaceuticals and laboratory leaders in precision oncology.

Stay tuned as Lunit continues to showcase its trailblazing work in AI-driven oncology, paving the way for a future where personalized cancer treatments become the norm rather than the exception. This focus on innovation affirms Lunit's leadership role in the global fight against cancer, promising better tools for physicians and better prognoses for patients.